Le Lézard
Classified in: Business
Subjects: EARNINGS, Conference Call, Webcast

Arrowhead Pharmaceuticals Reports Fiscal 2020 First Quarter Results


Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2019. The company is hosting a conference call at 4:30 p.m. EDT to discuss results.

Conference Call and Webcast Details

Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 6694317.

A replay of the webcast will be available on the company's website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 6694317.

Selected Recent Events

Selected Fiscal 2020 First Quarter Financial Results

ARROWHEAD PHARMACEUTICALS, INC.

CONSOLIDATED CONDENSED FINANCIAL INFORMATION (unaudited)

 

 

 

 

 

 

 

 

 

 

Three Months Ended December 31,

 

 

OPERATING SUMMARY

2019

 

 

2018

 

 

 

 

 

 

 

 

 

 

 

REVENUE

$

29,454,579

 

 

$

34,657,896

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

Research and development

 

23,373,616

 

 

 

17,572,043

 

 

General and administrative expenses

 

10,934,557

 

 

 

6,139,709

 

 

TOTAL OPERATING EXPENSES

 

34,308,173

 

 

 

23,711,752

 

 

OPERATING INCOME (LOSS)

 

(4,853,594

)

 

 

10,946,144

 

 

OTHER INCOME/(EXPENSE), PROVISION FOR INCOME TAXES

 

2,179,866

 

 

 

1,091,109

 

 

NET INCOME (LOSS)

$

(2,673,728

)

 

$

12,037,253

 

 

 

 

 

 

 

 

 

 

 

NET INCOME (LOSS) PER SHARE (DILUTED)

$

(0.03

)

 

$

0.13

 

 

WEIGHTED AVERAGE SHARES OUTSTANDING (DILUTED)

 

97,090,079

 

 

 

95,590,183

 

 

 

 

 

 

 

 

 

 

 

FINANCIAL POSITION SUMMARY

December 31,

 

 

September 30,

 

 

 

2019

 

 

2019

 

 

CASH AND CASH EQUIVALENTS

$

461,032,249

 

 

$

221,804,128

 

 

SHORT-TERM INVESTMENTS

 

40,969,341

 

 

 

36,899,894

 

 

LONG-TERM INVESTMENTS

 

26,329,098

 

 

 

44,175,993

 

 

TOTAL CASH RESOURCES (CASH AND INVESTMENTS)

 

528,330,688

 

 

 

302,880,015

 

 

OTHER ASSETS

 

59,270,946

 

 

 

46,965,422

 

 

TOTAL ASSETS

 

587,601,634

 

 

 

349,845,437

 

 

TOTAL CURRENT DEFERRED REVENUE

 

54,034,129

 

 

 

77,769,629

 

 

TOTAL LONG TERM DEFERRED REVENUE

 

-

 

 

 

5,035,142

 

 

OTHER LIABILITIES

 

34,038,862

 

 

 

23,004,414

 

 

TOTAL LIABILITIES

 

88,072,991

 

 

 

105,809,185

 

 

TOTAL STOCKHOLDERS' EQUITY

 

499,528,643

 

 

 

244,036,252

 

 

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

$

587,601,634

 

 

$

349,845,437

 

 

 

 

 

 

 

 

 

 

 

SHARES OUTSTANDING

 

101,111,797

 

 

 

95,506,271

 

 

 

 

 

 

 

 

 

 

 

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.


These press releases may also interest you

at 18:00
According to the latest report, "Recreational Boating Market by Product (Inboard Boats By Horsepower [Below 200 hp, 201 to 500 hp, 501to 1000 hp, Above 1000 hp], Outboard Boats By Type [Center Console, Express Cruiser, Pontoon, Runabout Bowrider,...

at 17:07
Platinum Decking has announced that it is expanding its operations by opening a branch in Chicago, Illinois. The announcement by the highly-rated decking company to become a Chicago deck builder comes after the company's first year of business in...

at 17:00
TorkLaw is now accepting COVID-19 Business Interruption Insurance Claim Denial cases on behalf of businesses who have had valid insurance claims denied by their insurance companies. Many States and local governments have mandated non-essential...

at 14:00
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of RTI Surgical Holdings, Inc. between March 7, 2016 and March 16, 2020, inclusive (the "Class Period"), of the important May 22, 2020 lead plaintiff deadline in...

at 13:30
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zoom Video Communications, Inc. ("Zoom" or "the Company") . Investors who purchased Zoom securities are encouraged to obtain...

at 12:24
Due to the uncertain macroeconomic situation as a result of the spread of the coronavirus in Europe, the Board of TF Bank has today decided to make an additional loan loss provision of SEK 30 million at the end of the first quarter of 2020. The...



News published on 5 february 2020 at 16:05 and distributed by: